Table 3 Risk factors for the presence of cardiovascular disease, the CKD-ROUTE study (Oct 2010 - Dec 2011)

Hypertension

4.07 [2.10 - 7.90 ]

<0.001

3.57 [1.82 - 7.02]

<0.001

Diabetes

2.32 [1.77 - 3.03]

<0.001

2.45 [1.86 - 3.23]

<0.001

Optimal BMI (18.5 to 24.9 kg/m²)

1 (reference)

1 (reference)

≥ 25 kg/m²

1.10 [0.82 - 1.49]

0.513

1.27 [0.93 - 1.74]

0.130

< 18.5 kg/m²

0.77 [0.43 -1.39]

0.391

0.74 [0.40 - 1.36]

0.329

Stage 2

1 (reference)

1 (reference)

Stage 3

3.57 [1.61 - 7.95]

0.002

2.56 [1.14 - 5.78]

0.023

Stage 4

6.98 [3.14 - 15.53]

<0.001

4.79 [2.12 - 10.81]

<0.001

Stage 5

5.55 [2.43 - 12.65]

<0.001

4.37 [1.89 - 10.11]

0.001

< 0.15 g/gCr

1 (reference)

1 (reference)

0.15 to 0.49 g/gCr

1.21 [0.78 - 1.89]

0.402

1.23 [0.78 - 1.94]

0.378

≥ 0.5 g/gCr

1.55 [1.11 - 2.16]

0.009

1.77 [1.26 - 2.50]

0.001

SBP ≥ 130 mmHg

0.90 [0.68 - 1.18]

0.438

0.93 [0.70 - 1.23]

0.600

3.92 [2.53 - 6.07]

<0.001

3.54 [2.27 - 5.53]

<0.001

Use of ARB or ACEI

1.72 [1.29 - 2.29]

<0.001

1.64 [1.22 - 2.20]

0.001

Use of calcium channel blocker

1.55 [1.19 - 2.02]

0.001

1.55 [1.18 - 2.03]

0.002

Use of diuretics

1.61 [1.08 - 2.38]

0.019

2.44 [1.84 - 3.24]

<0.001

Hb < 11 g/dl

1.63 [1.24 - 2.13]

<0.001

1.61 [1.21 - 2.15]

0.001

Iron deficiency

2.03 [1.40 - 2.94]

<0.001

2.41 [1.63 - 3.58]

<0.001

Use of ESA

2.10 [1.43 - 3.10]

<0.001

1.93 [1.29 - 2.89]

0.001

Use of oral iron supplementation

2.01 [1.17 - 3.44]

0.011

2.15 [1.22 - 3.80]

0.008

LDL-C ≥ 120 mg/dl

0.44 [0.31 - 0.61]

<0.001

0.49 [0.34 - 0.68]

<0.001

HDL-C < 40 mg/dl

2.45 [1.80 - 3.35]

<0.001

2.29 [1.66 - 3.16]

<0.001

TG ≥ 150 mg/dl

0.81 [0.61 - 1.08]

0.149

0.92 [0.69 - 1.23]

0.575

Use of statin

2.48 [1.88 - 3.27]

<0.001

2.73 [2.04 - 3.66]

<0.001

Corrected Ca < 8.4 mg/dl

0.49 [0.19 - 1.30]

0.152

0.46 [0.17 - 1.22]

0.118

P ≥ 4.6 mg/dl

1.12 [0.72 - 1.76]

0.611

1.34 [0.84 - 2.14]

0.214

Intact PTH > 65 pg/ml

1.80 [1.33 - 2.43]

<0.001

1.86 [1.36 - 2.54]

<0.001